EXCLUSIVE: Imunon Says Enrollment Momentum for Phase 3 OVATION 3 Trial of IMNN-001 in Advanced Ovarian Cancer Exceeds Expectations; Projects Enrollment to Complete in Q2 of 2029

Loading news article.

EXCLUSIVE: Imunon Says Enrollment Momentum for Phase 3 OVATION 3 Trial of IMNN-001 in Advanced Ovarian Cancer Exceeds Expectations; Projects Enrollment to Complete in Q2 of 2029 | WAPE

EXCLUSIVE: Imunon Says Enrollment Momentum for Phase 3 OVATION 3 Trial of IMNN-001 in Advanced Ovarian Cancer Exceeds Expectations; Projects Enrollment to Complete in Q2 of 2029

Article summary

Related companies

Comments —